XML 27 R3.htm IDEA: XBRL DOCUMENT v3.24.0.1Close
Consolidated Statements of Income - USD ($)
$ in Millions
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
 [1]
Dec. 31, 2021
 [1]
Revenues      
Premiums $ 44,237 $ 39,916 $ 41,154
Net investment income 1,166 1,155 1,549
TOTAL REVENUES 195,265 180,518 174,069 Close
Benefits and expenses      
Pharmacy and other service costs 133,801 124,834 117,553
Medical costs and other benefit expenses 36,287 32,184 33,565
Selling, general and administrative expenses 14,822 13,174 13,012
Amortization of acquired intangible assets 1,819 1,876 1,998
TOTAL BENEFITS AND EXPENSES 186,729 172,068 166,128 Close
Income from operations 8,536 8,450 7,941 Close
Interest expense and other (1,446) (1,228) (1,208) Close
Debt extinguishment costs 0 0 (141) Close
(Loss) gain on sale of businesses (1,499) 1,662 0 Close
Net realized investment (losses) gains (78) (487) 198 Close
Total Other Income Expenses -3023.0 -53.0 -1151.0 0 0 Close
Income before income taxes 5,513 8,397 6,790 CloseClose
TOTAL INCOME TAXES 141 1,615 1,370 Close
Net income 5,372 6,782 5,420 Close
Less: Net income attributable to noncontrolling interests 208 78 50
SHAREHOLDERS' NET INCOME $ 5,164 $ 6,704 $ 5,370
Shareholders' net income per share      
Basic (in dollars per share) $ 17.57 $ 21.66 $ 15.89
Diluted (in dollars per share) $ 17.39 $ 21.41 $ 15.75
Pharmacy revenues      
Revenues      
Revenues $ 137,243 $ 128,566 $ 121,413
Fees and other revenues      
Revenues      
Revenues $ 12,619 $ 10,881 $ 9,953
[1] Amounts have been restated to reflect the adoption of Targeted Improvements to the Accounting for Long-Duration Contracts in 2023. See Note 2 to the Consolidated Financial Statements for further information.